Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03805581
Other study ID # NYMC-192
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 12, 2018
Est. completion date November 7, 2023

Study information

Verified date December 2023
Source New York Medical College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 7, 2023
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years to 40 Years
Eligibility Inclusion Criteria: - SCD-associated ACS with the presence of any two or more of the following signs not explained by other etiologies: Fever, Chest pain, Cough, Dyspnea, Tachypnea for age, Pulmonary infiltrate on CXR and/or Chest CT scan, Decreased O2 saturation with or without oxygen supplement; - Age 2 to 40 years of age; - Homozygous Hemoglobin S Disease, Hemoglobin SC Disease or Hemoglobin S 0/+ thalassemia; - Informed consent/assent; - Consent of patient/parent within =72 hours after inpatient admission for SCD-associated ACS. - Females of childbearing age will have a negative pregnancy test. Exclusion Criteria: - Current Grade III or IV hemorrhage; - Previous hypersensitivity reaction to defibrotide; - Current systemic anti-coagulant therapy and/or fibrinolytic therapy; - Consent of patient/parent greater than 72 hours of inpatient admission for SCD-associated ACS; - No signed informed consent

Study Design


Intervention

Drug:
Defibrotide
Defibrotide 6.25 mg/kg IV q6h up to 7 days

Locations

Country Name City State
United States New York Medical College Valhalla New York

Sponsors (2)

Lead Sponsor Collaborator
New York Medical College Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with grade III/IV allergic reaction to defibrotide All patients will be monitored for allergic reaction probably or definitely related to defibrotide administration. 30 days
Primary Number of patients with grade III/IV hemorrhage All patients will be monitored for hemorrhage probably or definitely related to defibrotide. 30 days
Secondary Number of patients with improvement in clinical signs of Acute Chest Syndrome Patients will have pre and post treatment assessments with imaging and blood tests to monitor clinical signs of ACS 30 days
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02565082 - Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients N/A
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A